Enzyme replacement therapy of Fabry disease.
Fabry disease is an X-linked lysosomal storage disease caused by deficiency of the enzyme alpha-galactosidase A and results in pain, progressive renal impairment, cardiomyopathy, and cerebrovascular disease. The results of two major randomized, double-blind, placebo-controlled clinical trials and open-label extensions have shown that replacement of the deficient enzyme with either of two preparations of recombinant human alpha-galactosidase A, agalsidase-alfa, and agalsidase-beta is safe. Biweekly i.v. infusions of 0.2 mg/kg of agalsidase-alfa were associated with a significant decrease in pain and stabilization of renal function. Biweekly infusions of 1 mg/kg of agalsidase-beta were associated with virtually complete clearing of accumulated glycolipid substrate from renal and cutaneous capillary endothelial cells. Several smaller, open-label studies, along with observations made in the course of monitoring large numbers of patients on enzyme replacement therapy, indicated that treatment stabilizes renal function and produces significant improvements in myocardial mass and function. Treatment of Fabry disease by enzyme replacement has a significant impact on at least some serious complications of the disease.
Clarke
Joe T R
JT
Division of Clinical & Metabolic Genetics, Hospital for Sick Children, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Iwanochko
R Mark
RM
D041321:Chromosomes, Human, X; D000795:Fabry Disease / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D006801:Humans; D007527:Isoenzymes / Q000627:therapeutic use*; D010146:Pain; D011994:Recombinant Proteins; D000519:alpha-Galactosidase / Q000627:therapeutic use*
D007527:Isoenzymes; D011994:Recombinant Proteins; C000627036:agalsidase alfa; D000519:alpha-Galactosidase; C459420:agalsidase beta